Skip to main content
. Author manuscript; available in PMC: 2011 Feb 3.
Published in final edited form as: Nat Chem Biol. 2010 Jun 20;6(8):595–601. doi: 10.1038/nchembio.391

Figure 5.

Figure 5

Selective MCL-1 targeting by MCL-1 SAHBD sensitizes death receptor signaling and induces caspase-dependent cancer cell apoptosis. (a) Jurkat T-cell leukemia and (b) OPM2 cells were exposed to MCL-1 SAHBD singly and in combination with low dose death receptor agonists TRAIL and Fas ligand (FasL) in the presence or absence of the pan-caspase inhibitor, z-VAD. Cell viability measured by MTT assay at 24 hours revealed dose-responsive and caspase-dependent apoptosis sensitization of Jurkat (TRAIL and FasL) and OPM2 (TRAIL) cells by MCL-1 SAHBD. The capacity of MCL-1 SAHBD to sensitize (c) Jurkat and (d) OPM2 cells to death receptor stimuli correlated with dose-responsive activation of caspase 3/7, as measured by luminescence of DEVD-cleaved substrate. Data are mean and s.d. for experiments performed in at least triplicate. Vehicle, deionized water.